Plasminogen activator for the treatment of acute inflammatory and chronic interstitial lung diseases
Production of a recombinant chimeric fusion protein, consisting of human plasminogen activator (urokinase or u-PA) and human hydrophobic surfactant protein (SP-B, SP-C).<br>
Persistent suppression of alveolar fibrinolytic activity and the resulting permanent intra-alveolar fibrin deposition play an important pathomechanistic role in acute inflammatory and chronic interstitial lung diseases. In this process, the polymerization of fibrinogen to fibrin in the presence of lung surfactant causes incorporation of the surfactant into the growing fibrin matrix, which is associated with loss of surface activity, an altered fibrin structure, and enhanced resistance of fibrin to fibrinolytic proteases. In addition, the blocking of u-PA dependent processes is also linked with reduced activation of hepatocyte growth factor (HGF), which protects the epithelium.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
